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Abstract
Genetically relevant mouse models need to recapitulate the hallmarks of human disease by
permitting spatiotemporal gene targeting. This is especially important for replicating the biol-
ogy of complex diseases like cancer, where genetic events occur in a sporadic fashion
within developed somatic tissues. Though a number of renal tubule targeting mouse lines
have been developed their utility for the study of renal disease is limited by lack of inducibil-
ity and specificity. In this study we describe the generation and characterisation of two novel
mouse lines directing CreERT2 expression to renal tubular epithelia. The Pax8-CreERT2
transgenic line uses the mouse Pax8 promoter to direct expression of CreERT2 to all renal
tubular compartments (proximal and distal tubules as well as collecting ducts) whilst the
Slc22a6-CreERT2 knock-in line utilises the endogenous mouse Slc22a6 locus to specifically
target the epithelium of proximal renal tubules. Both lines show high organ and tissue speci-
ficity with no extrarenal activity detected. To establish the utility of these lines for the study
of renal cancer biology, Pax8-CreERT2 and Slc22a6-CreERT2 mice were crossed to condi-
tional Vhl knockout mice to induce long-term renal tubule specific Vhl deletion. These mod-
els exhibited renal specific activation of the hypoxia inducible factor pathway (a VHL target).
Our results establish Pax8-CreERT2 and Slc22a6-CreERT2 mice as valuable tools for the
investigation and modelling of complex renal biology and disease.
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Introduction
Genetically engineered mouse models (GEMM) have been instrumental in understanding the
basic principles of renal biology and disease. Relevant mouse models need to recapitulate the hall-
marks of human disease by permitting gene alteration to occur specifically within relevant cell
types, and appropriate stages of development. This is especially important for replicating the biol-
ogy of complex diseases like cancer, where genetic events occur in a sporadic fashion within
developed somatic tissues. Though a number of renal tubule targeting mouse lines have been
developed, their utility in the study of renal cancer biology is limited by lack of inducibility (Ksp-
cadherin Cre [1], homeobox B7 Cre [2], Aquaporin 2 Cre [3], γ-glutamyl transpeptidase Cre [4],
phosphoenolpyruvate carboxykinase Cre [5] and Six homeobox 2 Cre [6]) and/or specificity
(phosphoenolpyruvate carboxykinase Cre [5], and Paired box 8 rtTA [7]). To address this defi-
ciency in the field we set out to generate novel inducible mouse lines allowing investigation of
RCC biology by specifically directing genetic modifications in either the proximal tubule (the
presumed cell of origin [8]), or throughout all renal tubular epithelial compartments.
Conditional gene expression systems provide an excellent way of controlling gene expres-
sion and circumventing any developmental defect as well as early lethality associated with con-
ventional gene targeting. These models rely on the use of site-specific recombinases to control
the spatiotemporal mutation of the genome. The most common conditional approach uses the
bacteriophage Cre-Lox system, in which Cre recombinase recognises a pair of inverted repeat
DNA elements, or LoxP sites, and catalyses recombination resulting in deletion or inversion of
the intervening sequence [9]. Further temporal control can be achieved with an inducible Cre-
recombinase, CreERT2, a fusion protein of the Cre-recombinase coding sequence and a mutant
form of the ligand-binding domain of the oestrogen receptor (ERT2) [10]. Administration of
tamoxifen forces the dissociation of the ERT2-bound heat shock protein 90 (HSP90), allowing
CreERT2 to translocate into the nucleus and induce recombination.
Here we adapted the CreERT2 system for specific use in renal tubular epithelia. We describe
the development and characterisation of two genetically engineered mouse lines that allow for
spatial and temporal targeting of conditional mutations in either all tubular epithelial compart-
ments (Pax8-CreERT2 transgenic mice) or specifically in proximal tubular epithelial cells
(Slc22a6-CreERT2 knock-in mice). We further establish the utility of these lines for the study of
renal cancer biology (a malignancy of the renal tubular epithelium) by generating models of
renal specific deletion of the von Hippel-Lindau (VHL) gene, the most common genetic change
found in human renal cancer [11–13].
Materials and Methods
Ethics Statement
All experimental procedures were carried out in accordance to Home Office UK regulations
and the Animals (Scientific Procedures) Act 1986 (licence no. PPL 80/2465 and 80/2552). All
experimental protocols were approved by the Animal Welfare and Ethical Review Body
(AWERB) of the University of Cambridge CRUK Cambridge Institute. At the end of the study,
mice were euthanized by cervical dislocation, in accordance with stated Home Office UK
regulations.
Mice
We used the following mice: C57BL/6J and CD1 from Charles River laboratories, B6.129S4(C)-
Vhltm1Jae/J (Jax: 012933), FLPeR [14] (Jax: 003946) and Rosa26R [15] (Jax: 003474) reporter
mice from Jackson Laboratories.
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Construction of vector pPax8-CreERT2
We used the pPax8-rtTA plasmid [7] (kindly donated by Professor Robert Koesters, DKFZ,
Heidelberg, Germany) and replaced a 0.9 kb AscI/HpaI restricted fragment containing the
rtTA sequence with the CreERT2-pA (polyadenylation signal) sequence contained within a
2.2 kb AscI/HpaI fragment of the pCreERT2-pA plasmid [10] (kindly donated by Professor
David Tuveson, Cancer Research UK Cambridge Institute, UK).
Generation of Pax8-CreERT2 transgenic mice
For microinjection, pPax8-CreERT2 was digested with PspXI/NotI and the Pax8-CreERT2 cas-
sette (8.4 kb) was isolated via gel electrophoresis and gel extraction (Qiagen). The linear DNA
fragment was then microinjected into fertilised C57BL/6J embryos using standard procedures.
The Pax8-CreERT2 founder lines were bred with C57BL/6J wild type mice to determine germ-
line transmission.
Fluorescence in situ hybridisation (FISH)
We hybridised metaphase spreads from splenocytes derived from Pax8-CreERT2 transgenic
mice with the Pax8-CreERT2 probe using standard protocols. The Pax8-CreERT2 probe was
generated by incorporation with digoxigenin-11-dUTP (Roche) via PCR and detected with
monoclonal mouse anti-digoxin (Sigma-Aldrich) and Texas red conjugated goat anti-mouse
IgG (Molecular Probes). Images were captured using the SmartCapture software (Digital Scien-
tific, UK) and metaphases were karyotyped using the SmartType Karyotyper software (Digital
Scientific).
DNA sequencing
Sheared genomic DNA isolated from the liver of a Pax8-CreERT2 transgenic mouse (1 μg) was
subjected to Illumina paired-end DNA library preparation and PCR-amplified for six cycles.
Amplified libraries were sequenced using the HiSeq platform (Illumina) according to the man-
ufacturer’s protocol. Paired-end, 75 base reads were generated to an average of 3.5 fold cover-
age across the genome. In order to identify the insertion site of the Pax8-CreERT2 transgene,
sequencing reads were aligned with BWA version 0.5.10 [http://www.ncbi.nlm.nih.gov/
pubmed/19451168] to a modified C57BL/6J reference genome (GRCm38/mm10) with the
chromosome 2 Pax8 gene sequence removed and the Pax8-CreERT2 transgene included as a
separate contig. Read alignments to the Pax8-CreERT2 transgene were visualized using the
Intergrative Genomics Viewer [16] to determine the chromosome and position where the
read mates were clustered, indicating the site of transgene insertion. Sequencing data can be
downloaded from the European Nucleotide Archive website under sample accession number
ERS400266.
Construction of vector pSlc22a6-CreERT2-FHF
We used recombineering [17, 18] to retrieve a 10kb fragment from a mouse C57BL/6 back-
ground Bacterial Artificial Chromosome (BAC; RP23-457i11) containing the Slc22a6 locus.
Briefly, the plasmid pSC101-BAD-gbaAtet was electroporated into E. coli containing the RP23-
457i11 BAC to provide the recombinase. We activated the recombineering machinery and
introduced by electroporation a pBS vector containing two previously cloned 80 bp retrieving
arms (a 3’ arm and a 5’ arm) homologous to the ends of our chosen 10 kb Slc22a6 BAC region.
This induced retrieval of the Slc22a6 locus by homologous recombination between the BAC
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and the 3’ and 5’ arms of the pBS vector. The resulting vector (pBS-Slc22a6) consisted of the
Slc22a6 exons 1 to 6 (4 kb), 4.3kb upstream genomic sequence and 1.3kb of intron 6. We PCR
amplified 487 bp of the pBS-Slc22a6 plasmid including the gene start codon and 400bp of
upstream sequences using the 5’ primer 5’-CATCGGTACCCATCCTCCCTTGCCCTTCATT-
3’ and the 3’ primer 5’-TCGACCGGTAATGCAGGCAAATTTTGGTGTACGGTCAGTA
AATTGGACATGGGGCTGGGCCAGGCTGAGTGGTCAAT-3’. After cutting the PCR-frag-
ment with KpnI/AgeI it was ligated into the KpnI/AgeI site of the pCreERT2-pA plasmid
(p5’UTR-CreERT2) replacing the start codon of the Slc22a6 gene with the start codon of the
CreERT2 cassette. A synthesised oligonucleotide (Sigma, UK) containing unique HpaI and PacI
digestion sites (5’-GGTCACCGTTAACGCACAATGGCACAGAGGCCATCACAATGGCA
CAGAGGCCATTAATTAAGGTCACC-3’) was ligated into the BstEII site of pBS-Slc22a6.
The MfeI/PacI sites were used for the ligation of a 2.6kb MfeI/PacI fragment of p5’UTR-
CreERT2 re-instating the endogenous 5’ sequence of the mouse Slc22a6 locus and replacing the
gene start codon with the CreERT2 open reading frame (pBS-Slc22a6-CreERT2). Finally an
FRT-PGK-Hygromycin-pA-FRT selection cassette (kindly donated by Professor David Tuve-
son, Cancer Research UK Cambridge Institute, UK) was ligated into the HpaI/PacI sites of
pBS-Slc22a6-CreERT2, 3’ of the CreERT2 sequence and 5’ of the remaining endogenous Slc22a6
exon 1 to generate pSlc22a6-CreERT2-FHF. The identity and integrity of the final plasmid was
confirmed by Sanger sequencing.
Screening of electroporated ES cells
C57BL/6J embryonic stem cells (CRIB6.1, an ES line derived in house) were electroporated
with the pSlc22a6-CreERT2-FHF targeting construct. The ES cell colonies were then screened
for correct locus insertion by PCR amplification of: (1) a 4.6 kb DNA fragment using a forward
primer located upstream of the 5’ homology arm (5’-GCAGTGGTCCATTTAGCACA-3’) and
a reverse primer located in the CreERT2 cassette (5’-CAGGTTCTTGCGAACCTCAT-3’) and
(2) a 5.2kb DNA fragment using a forward primer located in the hygromycin selection cassette
(5’- AGCTTGTCGACGAAGTTCCTA-3’) and a reverse primer located within exon 7 of the
Slc22a6 gene (5’- GCCGAAAATCACCTGGATAA-3’). The PCR conditions were set as fol-
lows: 1 cycle of 1 min 95°C, 30 cycles of (15 sec 95°C, 30 sec 58°C, 5 min 68°C), 1 cycle of 7 min
68°C.
ES cell colonies that tested positive by PCR for correct insertion of the targeting vector into
the Slc22a6 locus were grown further and DNA was extracted using standard protocols. Puri-
fied DNA was digested with SpeI/EcoRV (for 5’ probe detection), HindIII (3’ probe) or SpeI
(internal probe) and used for Southern blotting. The 595bp 5’ external probe hybridised
upstream of the 5’ homology arm of the targeted locus and was amplified by PCR from wild
type C57BL/6J DNA using the following primers: forward 5’- AGCAGTTTTGGAAAGGC
TTC-3’ and reverse 5’- CCCTTGATGATCTTGTGGTTC-3’. The 590bp 3’ external probe
hybridised downstream of the 3’ homology arm of the targeted locus and was amplified by
PCR from wild type C57BL/6J DNA using the following primers: forward 5’- AAGGCTGTCT
GGCTTCCTCT-3’ and reverse 5’- GACCTCTCAGGCCTTTGACA -3’. Finally the 579bp
internal probe hybridised to the hygromycin selection cassette of the targeting vector and was
PCR amplified from it using the following primers: 5’- GATGTTGGCGACCTCGTATT-3’
and reverse 5’- GATGTAGGAGGGCGTGGATA-3’. The probes were labelled using NEBlot
kit (NEB) and Southern blotting was performed using standard protocols.
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Generation of Slc22a6-CreERT2 knock-in mice
Correctly targeted ES cells were karyotyped and injected into 8-cell embryos of CD1 mice,
which were then implanted into pseudopregnant CD1 females (Cancer Research UK Cam-
bridge Institute Transgenic core). Chimeric founders were mated with wild-type C57BL/6J
mice. Genotyped progeny that were positive for germline transmission were bred, and first
generation offspring that inherited the targeted allele with hygromycin were subsequently
mated with C57BL/6J mice. The hygromycin selection cassette was removed using FLPeR mice
[14]. The FLPeR was bred out of the mouse line after hygromycin cassette elimination.
Genotyping
Mouse genotypes from ear biopsies were determined using real time PCR with specific probes
designed for each gene (Transnetyx, Cordova, TN). Additional genotyping using PCR was
undertaken for the presence of Cre-recombinase (forward primer 5’- GCACTGATTTCGAC
CAGGTT-3’, reverse primer 5’- GCTAACCAGCGTTTTCGTTC-3’, 200bp product) and
hygromycin sequences (forward primer 5’-GATGTTGGCGACCTCGTATT-3’, reverse primer
5’-GATGTAGGAGGGCGTGGATA-3’, 579bp product). The PCR conditions were set as fol-
lows: 1 cycle of 1 min 95°C, 30 cycles of (15 sec 95°C, 30 sec 58°C, 1 min 68°C), 1 cycle of 5 min
68°C.
To confirm recombination of the Vhl allele DNA was extracted from fresh frozen renal sam-
ples and genotyped by PCR using the following primers: forward primer for floxed allele 5’-
CCGGAGTAGGATAAGTCAGCTGAG-30, forward primer for recombined allele 50-CTGGT
ACCCACGAAAGTGTC-30, common reverse primer 50-CTGACTTCCACTGATGCTTGT
CACAG-30 (400bp product for floxed allele, 200bp product for wild type and 250bp product
for recombined allele). The PCR conditions used were: 1 cycle of 10 min 94°C, 55 cycles of
(50 sec 95°C, 50 sec 58°C, 60 sec 72°C), 1 cycle of 5 min 72°C.
CreERT2 induction by tamoxifen
Tamoxifen (Sigma, UK) was dissolved in sunflower seed oil/ethanol mixture (10:1) at 20mg/
ml. Four to eight week mice were injected intraperitoneally with 100µl of tamoxifen (2mg) or
sunflower seed oil per day for 5 consecutive days.
Histology and immunohistochemistry
For detection of β-galactosidase activity, mice were euthanized either at 2 or 4 weeks post
tamoxifen induction and tissues (skin, fat, pancreas, stomach, small and large intestine, spleen,
liver, kidneys, bladder, genital tract, thymus, heart, lungs, muscle, salivary glands, thyroid,
brain, and bone) were dissected. Samples were fixed in 10% paraformaldehyde for 1 hour, incu-
bated for 48 hours in 20% sucrose in PBS at 4°C and then snap-frozen in liquid nitrogen and
stored at -80°C. Frozen sections (5μm) were freshly cut, washed in PBS and incubated in X-gal
solution (50mM Tris HCl pH 7.4, 5 mM Potassium Ferrocyanide, 5 mM Potassium Ferricya-
nide, 2 mMMgCl2, 0.02% NP40 and 1 mg/ml X-gal) in a humidified chamber for 18 hours at
37°C. The slides were then washed and counterstained with nuclear fast red or used for IHC.
Immunohistochemistry (IHC) was performed on either frozen or formalin fixed tissues
using standard protocols. Specificity of immunostaining was assessed by incubation in the
absence of primary antibody. We used the following primary antibodies: Aquaporin 1 (AQP1,
NB-600-749, 1:500; Novus Biologicals), THP (AF5175, 1:100; R&D), Aquaporin 2 (AQP2,
ab105171, 1:1000; Abcam), VHL (sc5575, 1:200; Santa Cruz), HIF2a (NB100-132, 1:150;
Novus Biologicals), CAIX (sc-25600, 1:200; Santa Cruz) and GLUT1 (ab14683, 1:350; Abcam).
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Secondary antibodies used were conjugated to HRP and developed with DAB. For review of
histology, slides were stained by haematoxylin and eosin (H&E). For quantification of VHL
expression stained tissue sections were scanned with the Aperio ScanScope (Aperio, Vista, CA)
and images were visualised and captured using the Aperio ImageScope program. Images were
processed using Fiji software by calculating the percentage of DAB positive cells relative to
total nuclear area of the field.
Results
Pax8-CreERT2 transgenic mice
Generation of Pax8-CreERT2 mice. To enable targeting of all renal tubular epithelial
compartments, we chose to target expression of CreERT2 to the kidney using the previously iso-
lated genetic control elements of the mouse Pax8 locus [7]. A Pax8-rtTA transgenic mouse
model generated from this locus directs high levels of expression of the reverse tetracycline-
dependent transactivator (rtTA) to all proximal, distal and collecting tubules with extrarenal
activity occurring only in a minority of hepatocytes [7]. We replaced the rtTA sequence of the
pPax8-rtTA plasmid with a CreERT2 coding sequence [10] (Fig 1A). Following pronuclear
injection of the 8.4-kb linearized Pax8-CreERT2 construct into C57BL/6 fertilised embryos, we
identified five transgenic founders among 17 offspring mice. One of those lines displaying
germline transmission was designated Pax8-CreERT2 and is described here.
Using fluorescence in situ hybridization we mapped the site of integration of the Pax8-
CreERT2 construct to mouse chromosome 6 (Fig 1B). Paired-end whole genome sequencing
was used to precisely map the transgene integration site within an intergenic region of chromo-
some 6qC1 (chr6:62,912,590–62,912,610; GRCh38/mm10).
Functional Pax8-CreERT2 activity in-vivo. To show functional expression of CreERT2 in-
vivo, we crossbred Pax8-CreERT2 mice with Rosa26R reporter mice. These mice carry a lacZ
Fig 1. Generation of Pax8-CreERT2 transgenic mice. (A) The previously published pPax8-rtTA plasmid [7] is shown in the top panel. The CreERT2 coding
sequence followed by a polyadenylation signal (pA) was used to replace the rtTA sequence of pPax8-rtTA and generate plasmid pPax8-CreERT2 (bottom
panel) containing 4.3kb of upstream regulatory sequence, complete exon 1 and intron 1, part of exon 2 and 0.8kb of intron 2 of the murine Pax8 gene. (B)
FISH analysis of metaphase spreads using pPax8-CreERT2 as probe (green) maps the integration site to chromosome 6 (arrowheads). A weaker signal from
the endogenous Pax8 locus can be detected on chromosome 2 (arrows).
doi:10.1371/journal.pone.0148055.g001
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gene whose expression requires excision of loxP-flanked stop sequences [15]. Double trans-
genic mice (Pax8-CreERT2/Rosa26R) were treated at 8 weeks of age with either tamoxifen or
sunflower seed oil (vehicle control) for 5 consecutive days. Two and four weeks post treatment
mice were sacrificed and kidneys and several other tissues collected. The kidneys of treated
Fig 2. Pax8-CreERT2 mediated β-galactosidase expression. (A) Enzymatic X-gal staining of cryosections of kidneys (top panels) derived from 10 week
old Pax8-CreERT2/Rosa26R mice either induced with tamoxifen (a, renal parenchyma; b, collecting ducts) or uninduced (c). Tamoxifen administration did not
induce β-galactosidase expression in any of the other major organs examined (representative tissues presented in bottom panels). (B) β-galactosidase
positivity was exclusively found in the tubular epithelium of the kidney of tamoxifen treated mice, with no staining observed in glomeruli or bloods vessels (a,
framed area is shown enlarged in b). Kidneys from vehicle treated mice were negative (c). Co-localisation studies revealed X-gal expression within tubules of
all renal tubular compartment (proximal tubules—AQP1, distal tubules–THP and collecting ducts–AQP2). Scale bars, 100μm.
doi:10.1371/journal.pone.0148055.g002
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mice but not those of control showed strong β-galactosidase expression in both the cortex and
medulla (Fig 2A). In contrast to the previously reported Pax8-rtTA transgenic mouse [7] no
expression was detected in the liver of Pax8-CreERT2/Rosa26R tamoxifen treated animals. Sim-
ilarly, no expression could be detected in any other tissue tested, including bladder, spleen and
brain (Fig 2A).
Closer examination of the kidney revealed β-galactosidase positivity in renal tubular epithe-
lial cells only. Parietal and visceral epithelial cells of glomeruli, mesangial cells and blood ves-
sels did not stain (Fig 2B). Co-localisation studies with renal tubular epithelial markers
revealed Pax8-CreERT2 mediated recombination in both proximal and distal tubules as well as
strong β-galactosidase expression in collecting ducts (Fig 2B). Recombination specificity and
efficiency did not vary between male and female mice.
Slc22a6-CreERT2 knock-in mice
Generation of Slc22a6-CreERT2 mice. To enable the specific targeting of proximal renal
tubular epithelia, the Slc22a6mouse locus was used to direct CreERT2 expression. Slc22a6
encodes a protein involved in the sodium-dependent transport and excretion of organic anions
(OAT1), and is exclusively expressed in the renal proximal tubules from late embryogenesis
and throughout adulthood [19, 20]. As the essential elements of its promoter have not been
defined, a knock-in approach was pursued for the generation of Slc22a6-CreERT2 mice.
We constructed a targeting vector in which a CreERT2 cassette was inserted immediately
downstream of the initiation methionine of the endogenous mouse Slc22a6 gene, followed by a
PGK-hygromycin sequence flanked by FRT sites (FHF) for selection of targeted embryonic
stem (ES) cells (Fig 3A). ES cells correctly targeted with the Slc22a6-CreERT2-FHF construct
were identified initially by PCR and then confirmed by Southern blotting using an external 5’
probe (9.3kb wild type and 5.8kb targeted DNA fragments from SpeI/EcoRV digested genomic
DNA), an external 3’ probe (12.7kb wild-type and 9.5kb targeted DNA fragments from HindIII
digested genomic DNA) and an internal probe (no wild type and 9.2kb targeted DNA frag-
ments from SpeI digested genomic DNA) (Fig 3B). Correctly targeted ES cells were injected
into C57BL/6 blastocysts to produce founder animals. Finally, the hygromycin selection cas-
sette was removed by mating progeny to FLPeR mice [14] (confirmed using PCR analysis, data
not shown) to generate Slc22a6-CreERT2 knock-in mice. Similar to conventional Slc22a6
knockout mice [21], heterozygous and homozygous Slc22a6-CreERT2 mice were viable and dis-
played no discernible developmental defects (data not shown).
Functional Slc22a6-CreERT2 activity in-vivo. To show functional expression of CreERT2
in-vivo, Slc22a6-CreERT2 mice were cross-bred with Rosa26R reporter mice. Double transgenic
mice (Slc22a6-CreERT2/Rosa26R) were treated at 8 weeks of age with either tamoxifen or sun-
flower seed oil (vehicle control) for 5 consecutive days. Two and four weeks post treatment
mice were sacrificed and kidneys and several other tissues collected. The kidneys of treated
mice but not those of control showed β-galactosidase expression which was limited to the renal
cortex (Fig 4A). Analysis of other tissues did not reveal any expression of β-galactosidase (Fig
4A). Closer examination of the kidney revealed β-galactosidase positivity in renal tubular epi-
thelial cells only. Parietal and visceral epithelial cells of glomeruli, mesangial cells and blood
vessels did not stain (Fig 4B). Co-localisation studies with renal tubular epithelial markers
revealed Slc22a6-CreERT2 mediated recombination in only proximal tubule epithelial cells and
not in epithelia of distal tubules or collecting ducts (Fig 4B). Recombination specificity and effi-
ciency did not vary between male and female mice.
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Fig 3. Generation of Slc22a6-CreERT2 knock-in mice. (A) Schematic diagram of the generation of Slc22a6-CreERT2 knock-in mice. The exon-intron
structure of the mouse Slc22a6 locus is shown at the top. The targeting vector has a 4.3 kb 50 arm that locates immediately upstream of the Slc22a6 gene
Renal Tubular Specific CreERT2 Recombination
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Renal tubule specific models of Vhl deletion
To determine the utility of our novel CreERT2 strains for the study of renal cancer we generated
renal tubular epithelial specific deletion models of Vhl, a gene deleted in ~80–90% of all clear
cell renal cancers [11–13]. Mice with a loxP-flanked Vhl allele (Vhlfl/fl) [22] were interbred with
either Pax8-CreERT2 trangenic mice to induce Vhl deletion throughout renal tubular epithelia,
or with Slc22a6-CreERT2 knock-in mice for specific proximal tubular epithelial deletion.
Pax8-CreERT2/Vhlfl/fl and Slc22a6-CreERT2/Vhlfl/fl compound mice (n = 4 respectively)
were tamoxifen induced at 4 weeks of age. Uninduced mice of the same genotype or Vhlfl/fl
mice treated with tamoxifen served as controls (n = 4). Cohorts were followed up to 15 months
of age, with no evidence of any morbidity or mortality. Recombination of Vhl was readily
detectable by genomic DNA PCR in the kidneys of tamoxifen treated compound mutant mice
(hereafter referred to as VhlΔ/Δ) but not in control animals (Fig 5A). Estimates of Vhl recombi-
nation efficiency between the two models were determined by analysis of VHL immunostain-
ing (Fig 5B). Renal expression levels of VHL in tamoxifen treated Pax8-CreERT2/VhlΔ/Δ and
Slc22a6-CreERT2/VhlΔ/Δ mice were on average 40% and 16% lower respectively than in control
kidneys (S1 Fig). VhlΔ/Δ kidneys from both lines were of normal external appearance and
parenchymal mass, and did not display histological abnormalities in the structure of the renal
tubules (Fig 5B), consistent with the phenotype described in previously published human and
mouse studies [23–25]. Similarly, we observed accumulation of HIF2a (a major target of the
VHL protein) and its downstream targets CAIX and GLUT1, as well as an increase in cortical
vascularisation [26] (Fig 5B), confirming renal specific loss of VHL in our models.
Discussion
Here we report the generation and characterisation of two novel mouse lines, Pax8-CreERT2
and Slc22a6-CreERT2, which allow for specific and temporal modification of target genes either
throughout the entire renal tubular epithelium or specifically in the proximal renal tubular
compartment. We further establish their utility for the investigation of renal cancer biology by
generating tractable renal tubule specific models of Vhl deletion.
Though a number of renal tubule targeting mouse lines have been described their utility in
the investigation of renal pathophysiology and complex renal disease, like cancer, is limited by
lack of inducibility [1–6, 27, 28], and cell-type and tissue specificity [7, 29–31]. In this study we
set out to address this deficiency by generating novel inducible mouse lines directing genetic
modifications in either specifically the proximal tubule (the presumed cell of origin of RCC
[8]) or throughout all renal tubular epithelial compartments.
For renal tubule-specific modulation we chose to express the inducible CreERT2 cassette
under the genetic control of the Pax8 promoter. Previously described Pax8-rtTA transgenic
mice, demonstrate highly efficient acute and chronic renal tubule targeting but are not directly
compatible with the Cre-loxP recombination system, requiring interbreeding with TetO-Cre
transgenic mice and hence complex breeding schedules [7]. Furthermore, kidney tubule-spe-
cific knockout of Vhl using the Pax8-rtTA line has been limited by the off-target deletion of
Vhl in a subset of hepatocytes leading to the development of clinically significant polycythae-
mia [12]. The Pax8-CreERT2 transgenic line described here shows efficient and specific trans-
gene expression in all renal tubular compartments (proximal, distal tubules and collecting
ATG, the CreERT2-pA coding sequence, a PGK-hygromycin selection cassette flanked by FRT sites (green triangles) and a 5.3 kb 30 arm that extends to
intron 6. (B) Southern blots show a control (wild-type) and 4 correctly targeted ES cell clones (77, 79, 92, 185) that give expected hybridisation patterns.
Clone 142 is incorrectly targeted. The location of 5’, 3’ and internal probes as well as expected band lengths are indicated in the diagrams on the right.
doi:10.1371/journal.pone.0148055.g003
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Fig 4. Slc22a6-CreERT2mediated β-galactosidase expression. (A) Enzymatic X-gal staining of cryosections of kidneys (top panels) derived from 10week
old Slc22a6-CreERT2/Rosa26Rmice either induced with tamoxifen (a, renal cortex; b, medulla) or uninduced (c, renal cortex). Tamoxifen administration did not
induce β-galactosidase expression in any of the other major organs examined (representative tissues presented in bottom panels). (B) β-galactosidase positivity
was exclusively found in the tubular epithelium of the kidney of tamoxifen treatedmice (a); kidneys from vehicle treatedmice were negative (b). Co-localisation
Renal Tubular Specific CreERT2 Recombination
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ducts) with high organ specificity and no extrarenal activity detected in any of the organs ana-
lysed, including the liver. This difference in expression pattern between the Pax8-rtTA and
Pax8-CreERT2 lines is likely to be due to the site of transgene integration (chromosome 8 band
2 and chromosome 6qC1 respectively), as exactly the same Pax8 promoter fragment directing
transgene expression is present in both lines. Importantly, the induction of Vhl deletion in
Pax8-CreERT2/Vhlfl/fl compound mice resulted in renal-specific loss of Vhl with no clinical
signs of polycythaemia, thus permitting the investigation of long-term effects of Vhl deletion
on renal physiology and disease.
Though two inducible mouse lines targeting the proximal renal tubule have been described
to date (γ-glutamyl transpeptidase CreERT2 [30] and solute carrier family 34-member 1
CreERT2 [29]), their specificity of expression outside of the kidney has not been fully character-
ised, limiting their utility for the generation of organ-specific disease models. We thus gener-
ated and characterised a novel mouse line (Slc22a6-CreERT2) expressing a CreERT2 cassette
from the endogenous promoter of Slc22a6, a gene exclusively expressed in renal proximal
tubules [19, 20]. As predicted, Slc22a6-CreERT2 mice direct recombination specifically in renal
proximal tubule epithelial cells with no expression detected in other renal cell types or any
other extrarenal tissue examined. We further established the utility of this line for the investiga-
tion of renal cancer biology by generating Slc22a6-CreERT2/Vhlfl/fl compound mice which
phenocopied previously published models [24–26] and exhibited no limiting morbidity or
mortality.
The CreERT2 mouse lines described in this study offer great flexibility in both the spatiotem-
poral distribution and the efficiency of recombination achieved. The knock-in Slc22a6-
CreERT2 line drives highly specific recombination in the proximal tubules but with relatively
low efficiency, as expected by integration of a single copy of the CreERT2 cassette in a native
mouse locus. This line represents a powerful tool for the study of clonal physiology and pathol-
ogy of the proximal tubule, such as in studies of cell fate determination during development,
tissue maintenance and repair (lineage tracing and genetic labelling approaches) and the inves-
tigation of renal cancer initiation and progression. In contrast, the Pax8-CreERT2 transgenic
line (multiple copy integration) allows for the genetic modification of multiple renal tubular
subtypes with high efficiency permitting more general, agnostic approaches in the investigation
of renal biology and disease.
In this study we restricted analyses to CreERT2 induction of fully developed renal tubular
epithelia. The Pax8-CreERT2 and Slc22a6-CreERT2 mouse lines would also permit targeting of
renal tubules within early stages of development. Determination of the optimum dosing sched-
ule and efficiency of recombination at embryonic or neonatal tissues will require investigation
in additional studies.
Modelling clinically relevant renal disease requires the accurate genetic modification of rele-
vant cell types (cell of origin) within an appropriate time frame (early organogenesis versus full
differentiation). The Pax8-CreERT2 and Slc22a6-CreERT2 mouse lines described here exhibit
high tissue specificity and inducibility and therefore represent powerful new tools for renal
research.
studies revealed specific X-gal expression within proximal tubular epithelium (AQP1) with no expression detected in distal tubules (THP) or collecting ducts
(AQP2). Scale bars, 100μm.
doi:10.1371/journal.pone.0148055.g004
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Fig 5. Renal tubule specific models of Vhl deletion. (A) PCR analysis of recombination at the Vhl locus in the kidneys of mice with combinations of Pax8-
CreERT2, Slc22a6-CreERT2 and the Vhl floxed (fl) and wild-type (+) alleles. The positions of the bands representing the Vhl floxed, wild type (Wt) and
recombined (Δ) alleles are indicated. (B) Histological images of representative renal sections from 12 month old control, Pax8-CreERT2/VhlΔ/Δ and Slc22a6-
CreERT2/VhlΔ/Δmice (stains and antibodies as indicated, arrowheads indicate abnormal vascularisation). Scale bars, 100μm.
doi:10.1371/journal.pone.0148055.g005
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Supporting Information
S1 Fig. Pax8-CreERT2/VhlΔ/Δ and Slc22a6-CreERT2/VhlΔ/Δ recombination efficiency. Repre-
sentative images of VHL immunohistochemistry (A) and corresponding relative quantification
of VHL protein expression levels (B) in the kidneys of 12 month old control (n = 3), Pax8-
CreERT2/VhlΔ/Δ (n = 4) and Slc22a6-CreERT2/VhlΔ/Δ (n = 4) mice. Data represent mean ± s.e.
m.
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